Ancylostoma caninum Anticoagulant Peptide Blocks Metastasis In Vivo and Inhibits Factor Xa Binding to Melanoma Cells In Vitro

Summary

We evaluated the in vivo anti-metastatic activity of recombinant Ancylostoma caninum Anticoagulant Peptide (rAcAP), a potent (K_i = 265 pM) and specific active site inhibitor of human coagulation factor Xa originally isolated from bloodfeeding hookworms. Subcutaneous injection of SCID mice with rAcAP (0.01-0.2 mg/mouse) prior to tail vein injection of LOX human melanoma cells resulted in a dose dependent reduction in pulmonary metastases. In order to elucidate potential mechanisms of rAcAP’s anti-metastatic activity, experiments were carried out to identify specific interactions between factor Xa and LOX. Binding of biotinylated factor Xa to LOX monolayers was both specific and saturable (K_d = 15 nM). Competition experiments using antibodies to previously identified factor Xa binding proteins, including factor V/Va, effector cell protease receptor-1, and tissue factor pathway inhibitor failed to implicate any of these molecules as significant binding sites for Factor Xa. Functional prothrombinase activity was also supported by LOX, with a half maximal rate of thrombin generation detected at a factor Xa concentration of 2.4 nM. Additional competition experiments using an excess of either rAcAP or active site blocked factor Xa (EGR-Xa) revealed that most of the total factor Xa binding to LOX is mediated via interaction with the enzyme’s active site, predicting that the vast majority of cell-associated factor Xa does not participate directly in thrombin generation. In addition to establishing two distinct mechanisms of factor Xa binding to melanoma, these data raise the possibility that rAcAP’s antimetastatic effect in vivo might involve novel non-coagulant pathways, perhaps via inhibition of active-site mediated interactions between factor Xa and tumor cells.

• References

• 1 Murray JC. Coagulation and cancer. Br J Cancer 1991; 64: 422-4.
• 2 Bick RL, Pegram M. Syndromes of hypercoagulability and thrombosis: a review. Semin Thromb Hemost 1994; 20: 109-32.
• 3 Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31.
• 4 Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104-16.
• 5 Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: A cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-67.
• 6 Esumi N, Todo S, Imashuku S. Platelet aggregating activity mediated by thrombin generation in the NCG human neuroblastoma cell line. Cancer Res 1987; 47: 2129-35.
• 7 Boukerche H, Berthier-Vergnes O, Penin F, Tabone E, Lizard G, Bailly M, McGregor JL. Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets. Br J Haematol 1994; 87: 763-72.
• 8 Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-6.
• 9 Klepfish A, Greco A, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer 1993; 53: 978-82.
• 10 Zacharski LR, Memoli VA, Ornstein DL, Rouseau SM, Kisiel W, Kudryk BJ. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993; 85: 1225-30.
• 11 Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J, Goltzman D. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992; 267: 14151-6.
• 12 Kirchheimer JC, Christ G, Binder BR. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur J Biochem 1989; 181: 103-7.
• 13 Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased α_IIbβ₃ expression on the cell surface. Thromb Res 1992; 68: 233-45.
• 14 Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992; 10: 145-55.
• 15 Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-9.
• 16 Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991; 87: 229-36.
• 17 Fischer EG, Ruf W, Mueller BM. Tissue factor-initiated thrombin generation activates the signalling thrombin receptor on malignant melanoma cells. Cancer Res 1995; 55: 1629-32.
• 18 Stahl A Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54: 3066-71.
• 19 Altieri DC, Stamnes SJ. Protease-dependent T cell activation: Ligation of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte proliferation. Cell Immunol 1994; 155: 372-83.
• 20 Duchosal MA, Rothermel AL, McConahey PJ, Dixon FJ, Altieri DC. In vivo immunosupression by targeting a novel protease receptor. Nature 1996; 380: 352-6.
• 21 Altieri DC. Xa receptor EPR-1. FASEB J 1995; 9: 860-5.
• 22 Adida C, Ambrosini G, Plescia J, Crotty PL, Costa J, Altieri DA. Protease receptors in Hodgkin’s disease: Expression of the factor Xa receptor, Effector cell protease receptor-1, in Reed-Sternberg cells. Blood 1996; 88: 1457-64.
• 23 Kakkar AK, Lemoine NR, Stone SR, Altieri DA, Williamson RC. Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells. Clin Molec Pathol 1995; 48: M288-M90.
• 24 Ambrosini G, Altieri DC. Molecular dissection of effector cell protease receptor-1 recognition of factor Xa: Assignment of critical residues involved in antibody reactivity and ligand binding. J Biol Chem 1996; 271: 1243-8.
• 25 Ambrosini G, Plescia J, Chu KC, High KA, Altieri DC. Activation-dependent exposure of the inter-EGF sequence Leu⁸³-Leu⁸⁸ in factor Xa mediates ligand binding to effector cell protease receptor-1. J Biol Chem 1997; 272: 8340-5.
• 26 Sakai T, Kisiel W. Binding of human factors X and Xa to Hep G2 and J82 human tumor cell lines: Evidence that factor Xa binds to tumor cells independent of factor Va. J Biol Chem 1990; 265: 9105-13.
• 27 Kazama Y, Komiyama Y, Kisiel W. Tissue factor pathway inhibitor and protease nexin-1 are major factor Xa binding proteins on the HepG2 cell surface. Blood 1993; 81: 676-82.
• 28 Nicholoson AC, Nachman RL, Altieri DA, Summers BD, Ruf W, Edging-ton TS, Hajjar DP. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem 1996; 271: 28407-13.
• 29 Gajdusek C, Carbon S, Ross R, Nawroth P, Stern D. Activation of coagulation releases endothelial cell mitogens. J Cell Biol 1986; 103: 419-28.
• 30 Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S are potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-20.
• 31 Cappello M, Vlasuk GP, Bergum PW, Huang S, Hotez PJ. Ancylostoma caninum anticoagulant peptide: A hookworm-derived inhibitor of human coagulation factor Xa. Proc Natl Acad Sci USA 1995; 92: 6152-6.
• 32 Stanssens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GP. Anticoagulant repertoire of the hookworm Ancylostoma caninum . Proc Natl Acad Sci USA 1996; 93: 2149-54.
• 33 Cappello M, Hawdon JM, Jones BF, Kennedy WP, Hotez PJ. Ancylostoma caninum anticoagulant peptide: cloning by PCR and expression of soluble, active protein in E. coli. Molecular Biochem Parasitol 1996; 80: 113-7.
• 34 Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of anti-stasin: An inhibitor of metastasis and coagulation. J Biol Chem 1987; 262: 9718-23.
• 35 Fodstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A. A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer 1988; 41: 442-9.
• 36 Altieri DC, Edgington TS. Identification of effector cell protease receptor-1: a leukocyte-distributed receptor for the serine protease factor Xa. J Immunol 1990; 145: 246-53.
• 37 Carson SD, Ross SE, Bach R, Guha A. An inhibitory monoclonal antibody against human tissue factor. Blood 1987; 70: 490-3.
• 38 Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem 1986; 159: 109-13.
• 39 Gasic GJ, Viner ED, Budzynski AZ, Gasic GP. Inhibition of lung tumor colonization by leech salivary gland extracts from Haementeria ghilianii . Cancer Res 1983; 43: 1633-6.
• 40 Rieu P, Ueda T, Haruta I, Sharma CP, Arnout MA. The A-domain of β2 integrin CR3 (CD11b/CD18) is a receptor for the hookworm-derived neutrophil adhesion inhibitor NIF. J Cell Biol 1994; 127: 2081-91.
• 41 Hasan AAK, Cines DB, Ngaiza JR, Jaffe EA, Schmaier AH. High-molcular weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium. Blood 1995; 85: 3134-43.
• 42 Bouchard BA, Catcher CS, Thrash BR, Adida C, Tracy PB. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem 1997; 272: 9244-51.
• 43 Esumi N, Fan D, Fidler IJ. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1991; 51: 4549-56.
• 44 Camerer E, Rottingen J, Iversen J, Prydz H. Coagulation factors VII and X induce Ca²⁺ oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem 1996; 271: 29034-42.